Masimo (MASI)
(Delayed Data from NSDQ)
$115.05 USD
+1.03 (0.90%)
Updated Sep 4, 2024 04:00 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
Company Summary
Irvine, CA-based Masimo Corporation develops, manufactures and markets a family of non-invasive monitoring systems. The company has two segments: Healthcare revenues (62.3% of FY23 revenues, down 4.8% from FY22) and Non-healthcare revenues (37.7%, up 11.1%).
Masimo derives the majority of its Healthcare segment revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment (ii) other direct sales of non-invasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct ...
Company Summary
Irvine, CA-based Masimo Corporation develops, manufactures and markets a family of non-invasive monitoring systems. The company has two segments: Healthcare revenues (62.3% of FY23 revenues, down 4.8% from FY22) and Non-healthcare revenues (37.7%, up 11.1%).
Masimo derives the majority of its Healthcare segment revenue from four primary sources: (i) direct sales under deferred equipment agreements with end-user hospitals where the company provides up-front monitoring equipment at no up-front charge in exchange for a multi-year sensor purchase commitment (ii) other direct sales of non-invasive monitoring solutions to end-user hospitals, emergency medical response organizations and other direct customers (iii) sales of non-invasive monitoring solutions to distributors (iv) sales of integrated circuit boards to original equipment manufacturer (OEM) customers who incorporate the company’s embedded software technology into their multiparameter monitoring devices.
Notable products include Masimo’s flagship Signal Extraction Technology (SET) Pulse Oximetry, which monitors blood oxygen saturation levels and protect against hypoxemia and hyperoxemia. The device also measures pulse rate. The company has also ventured into non-invasive blood constituent, brain and breathe monitoring. Its rainbow Pulse CO-Oximetry measures blood constituents that include non-invasive hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet) and SET measurements of oxygen saturation (SpO2), pulse rate (PR), perfusion index (PI) and pleth variability index (PVi).
Rainbow Acoustic Monitoring measures respiration rate (RRa) non-invasively and on a continuous basis. SedLine monitors the brain functioning of patients under anesthesia or sedation. The company also provides Capnography and Multigas Monitoring OEM solutions.
Non-healthcare revenue is related to hardware and embedded software integrated into final products that are manufactured and sold by the company.
On Apr 11, 2022, Masimo acquired Viper Holdings Corporation, the parent company of DEI Sales, Inc., which owns Sound United, a consumer technology company that owns a portfolio of premium brands, including Bowers & Wilkins, Denon, Polk Audio and Marantz.
General Information
Masimo Corporation
52 DISCOVERY
IRVINE, CA 92618
Phone: 949-297-7000
Fax: 949-297-7001
Email: ekammerman@masimo.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/5/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.84 |
Current Year EPS Consensus Estimate | 3.87 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/5/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 114.02 |
52 Week High | 153.93 |
52 Week Low | 75.22 |
Beta | 0.98 |
20 Day Moving Average | 441,189.09 |
Target Price Consensus | 145.33 |
4 Week | -6.29 |
12 Week | -13.23 |
YTD | -1.84 |
4 Week | -11.73 |
12 Week | -14.79 |
YTD | -15.18 |
Shares Outstanding (millions) | 53.20 |
Market Capitalization (millions) | 6,120.29 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $NA |
Fundamental Ratios
P/E (F1) | 29.73 |
Trailing 12 Months | 32.78 |
PEG Ratio | NA |
vs. Previous Year | 38.71% |
vs. Previous Quarter | 11.69% |
vs. Previous Year | 9.01% |
vs. Previous Quarter | 0.71% |
Price/Book | 4.47 |
Price/Cash Flow | 19.96 |
Price / Sales | 3.03 |
6/30/24 | 14.07 |
3/31/24 | 13.26 |
12/31/23 | 13.77 |
6/30/24 | 6.36 |
3/31/24 | 5.87 |
12/31/23 | 5.98 |
6/30/24 | 2.09 |
3/31/24 | 2.31 |
12/31/23 | 2.18 |
6/30/24 | 1.15 |
3/31/24 | 1.31 |
12/31/23 | 1.22 |
6/30/24 | 9.38 |
3/31/24 | 8.92 |
12/31/23 | 8.88 |
6/30/24 | 3.94 |
3/31/24 | 4.01 |
12/31/23 | 3.98 |
6/30/24 | 4.06 |
3/31/24 | 4.39 |
12/31/23 | 4.30 |
6/30/24 | 25.73 |
3/31/24 | 25.72 |
12/31/23 | 25.79 |
6/30/24 | 1.90 |
3/31/24 | 1.86 |
12/31/23 | 1.92 |
6/30/24 | 0.55 |
3/31/24 | 0.62 |
12/31/23 | 0.64 |
6/30/24 | 35.29 |
3/31/24 | 38.13 |
12/31/23 | 38.98 |